AZILSARTAN KAMEDOXOMIL

Other

Brand names: Edarbi

Oral

Mechanism of Action

12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis. An AT 2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,

Indications

1 INDICATIONS AND USAGE Edarbi is indicated for the treatment of hypertension in adults

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes

including

as appropriate

lipid control

FDA Warnings

5 WARNINGS AND PRECAUTIONS Correct volume or salt depletion prior to administration of Edarbi
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
, patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death

Known Side Effects

11 documented side effects by frequency

Dizziness

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Fatigue

1-10%

High Blood Pressure

1-10%

Headache

1-10%

Low Blood Pressure

1-10%

General Unwellness

1-10%

Decreased Appetite

0.1-1%

Shortness of Breath

0.1-1%

Community Discussions

No community discussions found for AZILSARTAN KAMEDOXOMIL yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral